Use of mirabegron in treating overactive bladder

International Urogynecology Journal

Volumn 23, Issue 10, 2012, Pages 1345-1348

  Bhide, Alka A ^a   Digesu, G Alessandro ^a   Fernando, Ruwan ^a   Khullar, Vik ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Mirabegron; Overactive bladder; Safety; 3 adrenoreceptors

Indexed keywords

EID: 84868379633     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1724-0     Document Type: Review

References (15)

1. Tyagi P, Thomas CA, Yoshimura N, Chancellor MB (2009) Investigations into the presence of functional Beta1, Beta2 and Beta3- adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol 35(1):76-83
2. Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB et al (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 377 (4-6):437-448
3. Digesu GA, Basra R, Khullar V, Hendricken C, Camarata M, Kelleher C (2009) Bladder sensations during filling cystometry are different according to urodynamic diagnosis. Neurourol Urodyn 28(3):191-196
4. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T et al (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288 (3):1367-1373 (Pubitemid 29254179)
5. Takeda H, Yamazaki Y, AkahaneM, Igawa Y, Ajisawa Y, Nishizawa O (2000) Role of the beta(3)-adrenoceptor in urine storage in the rat: comparison between the selective beta(3)-adrenoceptor agonist, CL316, 243, and various smooth muscle relaxants. J Pharmacol Exp Ther 293(3):939-945 (Pubitemid 30417861)
6. Igawa Y, Aizawa N, Homma Y (2010) Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 51(12):811-818
7. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2- phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321(2):642-647 (Pubitemid 46624504)
8. van Gelderen EM, Li Q, Meijer J (2009) An exploratory comparison of the single dose pharmacokinetics of the beta 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Phamacol Ther 85(suppl 1):S88
9. Chapple CR, Yamaguchi O, Ridder A, Liehne J, Carl S, Mattiasson A et al (2008) Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 7(3):239
10. Chapple C, Wyndaele JJ, Van Kerrebroeck P, Radziszewski P, Dvorak V, Boerrigter P (2010) Dose-ranging study of oncedaily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol Suppl 9(2):249
11. Khullar V, Cambronero J, Stroberg P, Angulo J, Boerrigter P, Blauwet MB et al (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder-results from a European- Australian Phase III trial. Eur Urol Suppl 10(2):278-279
12. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The Selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in pateints with overactive bladder syndrome. J Urol 185(4):e783-e784
13. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 54(3):543-562
14. Krauwinkel WJ, van Gelderen EM, Groen MJ (2010) An openlabel, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. American Society for Clinical Pharmacolgy and Therapeutics Annual Meeting Abs PIII-65
15. Veltkamp S, van Gelderen M, Schaddelee M (2009) Clinical study into the pharmacokinetic, pharmacodynamic and safety interaction of the novel b3-adrenoreceptor agonist mirabegron and metformin in healthy subjects. Basic Clin Pharmacol Toxicol 105(Suppl):146